



Pietro L Vernazza

Contact

Pietro L Vernazza

Publications (8)

Albrecht S, Grässli F, Cusini A, Brucher A, Goppel S, Betschon E, Möller J, Ortner M, Ruetti M, Stocker R, Vuichard-Gysin D, Besold U, Risch L, von Kietzell M, Schlegel M, Vernazza P, Kuster S, Kahlert C, Kohler P. SARS-CoV-2 immunity and reasons for non-vaccination among healthcare workers from eastern and northern Switzerland: results from a nested multicentre cross-sectional study. *Swiss Med Wkly* 2024; 154:3734.

Lichtensteiger C, Koblischke M, Berner F, Jochum A, Sinnberg T, Balciunaite B, Purde M, Walter V, Abdou M, Hofmeister K, Kohler P, Vernazza P, Albrich W, Kahlert C, Zoufaly A, Traugott M, Kern L, Pietsch U, Kleger G, Filipovic M, Kneilling M, Cozzio A, Pop O, Bomze D, Bergthaler A, Hasan A, Aberle J, Flatz L. Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients. *J Autoimmun* 2023; 140:103118.

Bertisch B, Schaetti C, Schmid P, Peter L, Vernazza P, Isler M, Oppliger R, Schmidt A. Reply to 'Assessing the hepatitis C epidemiology in Switzerland: It's not that trivial'. *J Viral Hepat* 2023; 31:53-56.

Kahlert C, Strahm C, Güsewell S, Cusini A, Brucher A, Goppel S, Möller E, Möller J, Ortner M, Ruetti M, Stocker R, Vuichard-Gysin D, Besold U, McGeer A, Risch L, Friedl A, Schlegel M, Vernazza P, Kuster S, Kohler P, SURPRISE (SURveillance of infectious diseases among health PROfessionals In SwitzErland) Study Group. Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. *Clin Infect Dis* 2023; 77:194-202.

Kohler P, Babouee Flury B, Güsewell S, Egger T, Leal-Neto O, Brucher A, Lemmenmeier E, Meier Kleeb D, Möller J, Ortner M, Rieder P, Ruetti M, Schmid H, Stocker R, Vuichard-Gysin D, Speer O, Wiggli B, Besold U, McGeer A, Risch L, Friedl A, Schlegel M, Vernazza P, Kahlert C, Kuster S, SURPRISE Study Group. Clinical symptoms of SARS-CoV-2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination-A prospective multicentre cohort of health professionals (SURPRISE study). *Influenza Other Respir Viruses* 2023; 17:e13167.

Bertisch B, Schaetti C, Schmid P, Peter L, Vernazza P, Isler M, Oppliger R, Schmidt A. Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets. *J Viral Hepat* 2023; 30:667-684.

Sumer J, Keckeis K, Scanferla G, Frischknecht M, Notter J, Steffen A, Kohler P, Schmid P, Roth B, Wissel K, Vernazza P, Klein P, Schoop R, Albrich W. Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults-A randomized blinded controlled trial. *Front Med (Lausanne)* 2023; 10:948787.

Hovaguimian F, Martin-Diener E, Reinacher M, Rasi M, Schmidt A, Bernasconi E, Boffi El Amari E, Braun D, Calmy A, Darling K, Christinet V, Depmeier C, Hauser-Kronberger C, Läuchli S, Notter J, Stoeckle M, Surial B, Vernazza P, Bruggmann P, Tarr P, Haerry D, Bize R, Low N, Lehner A, Böni J, Kouyos R, Fehr J, Hampel B. Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection. *HIV Med* 2021; 23:146-158.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch